GlassScriptPhysician profile
Jeffrey L Ortstadt
NPI 1467480376
$7,861.59
in general payments reported to CMS, 2019-2025
56 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,050 · 2020: $1,783 · 2021: $2,914 · 2022: $591 · 2023: $446 · 2024: $78.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $523.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $847.39 | 2019-2024 | |
| Allergan, INC. | $757.17 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $701.98 | 2019-2023 | |
| Amgen INC. | $480.61 | 2019-2021 | |
| Biogen, INC. | $379.36 | 2019-2021 | |
| Genzyme Corporation | $333.46 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $310.91 | 2019-2023 | Austedo |
| Emd Serono, INC. | $280.90 | 2019-2022 | |
| Ucb, INC. | $254.05 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $248.72 | 2019-2022 | |
| Harmony Biosciences LLC | $242.70 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $225.96 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $187.40 | 2021 | |
| Avanir Pharmaceuticals, INC. | $160.22 | 2019-2021 | |
| Lilly USA, LLC | $157.18 | 2019-2023 | Emgality, Reyvow |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Ortstadt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.